Top 5 Stocks to Buy Now
→ 25-Cent Gold Explorer Set to Drill Top Canadian Mineral Belt (From Resource Stock Digest) (Ad)tc pixel
Thomas Shrader

Thomas Shrader Analyst Performance

Equity Research Analyst at BTIG Research

Thomas Shrader is a stock analyst at BTIG Research focused in the medical sector, covering 31 publicly traded companies. Over the past year, Thomas Shrader has issued 73 stock ratings, including strong buy, buy, and hold recommendations. While full access to Thomas Shrader's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Thomas Shrader's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
100 Last 10 Years
Buy Recommendations
93.00% 93 Buy Ratings
Companies Covered
31 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy1.0%1 ratings
Buy92.0%92 ratings
Hold7.0%7 ratings
Sell0.0%0 ratings

Out of 100 total stock ratings issued by Thomas Shrader at BTIG Research, the majority (92.0%) have been Buy recommendations, followed by 7.0% Hold and 1.0% Strong Buy.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
93.5% of companies on NASDAQ
29 companies
NYSE
6.5% of companies on NYSE
2 companies

Thomas Shrader, an analyst at BTIG Research, currently covers 31 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
29 companies		93.5%
Manufacturing
2 companies		6.5%

Thomas Shrader of BTIG Research specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
22 companies		71.0%
MED - DRUGS
6 companies		19.4%
PHARMACEUTICAL PREPARATIONS
1 company		3.2%
Miscellaneous
1 company		3.2%
MEDICAL SERVICES
1 company		3.2%

About Thomas Shrader

Thomas Shrader, PhD, CFA, is a Managing Director and Healthcare Analyst at BTIG. He provides coverage of the biotechnology sector, with a focus on large and smidcap companies. Previously, he was a Biotechnology Research Analyst at Stifel. Earlier in his career, Mr. Shrader was on the Biochemistry Faculty at the Albert Einstein College of Medicine. He earned a BA from The Johns Hopkins University, a PhD from Yale University and was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology.
Follow on LinkedIn

Thomas Shrader's Ratings History at BTIG Research

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
6/16/2026Reiterated Rating$3.90$12.00Buy
Novavax, Inc. stock logo
NVAX
Novavax
6/11/2026Reiterated Rating$9.03$19.00Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
6/9/2026Reiterated Rating$0.98$10.00Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
6/1/2026Reiterated Rating$1.14$10.00Buy
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
5/26/2026Reiterated Rating$5.34$15.00Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
5/18/2026Reiterated Rating$1.21$10.00Buy
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
5/13/2026Initiated Coverage$18.19$40.00Buy
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
5/13/2026Reiterated Rating$10.67$14.00Buy
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
5/13/2026Initiated Coverage$19.14$40.00Buy
Harrow, Inc. stock logo
HROW
Harrow
5/12/2026Reiterated Rating$29.03$63.00Buy
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
5/11/2026Reiterated Rating$19.62$39.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
5/11/2026Reiterated Rating$32.89$39.00Buy
AC Immune stock logo
ACIU
AC Immune
5/4/2026Reiterated Rating$2.98$8.00Buy
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
4/24/2026Initiated Coverage$4.79$15.00Buy
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
4/24/2026Initiated Coverage$4.78$15.00Buy
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
4/20/2026Reiterated Rating$9.22$14.00Buy
Harrow, Inc. stock logo
HROW
Harrow
4/17/2026Reiterated Rating$40.65$63.00Buy
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
3/30/2026Reiterated Rating$70.10$147.00Buy
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
3/26/2026Reiterated Rating$2.53$8.00Buy
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3/26/2026Reiterated Rating$2.46$4.00Buy
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3/25/2026Boost Price Target$22.47$38.00Buy
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
3/24/2026Reiterated Rating$1.92$25.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3/19/2026Reiterated Rating$31.02$39.00Buy
Harrow, Inc. stock logo
HROW
Harrow
3/18/2026Reiterated Rating$35.21$63.00Buy
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
3/17/2026Reiterated Rating$1.24Buy
AC Immune stock logo
ACIU
AC Immune
3/16/2026Reiterated Rating$3.02$8.00Buy
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
3/16/2026Boost Price Target$3.34$8.00Buy
Alector, Inc. stock logo
ALEC
Alector
3/10/2026Upgrade$2.19$6.00Buy
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
3/2/2026Boost Price Target$4.16$12.00Buy
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3/2/2026Boost Price Target$21.18$36.00Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
2/26/2026Reiterated Rating$1.71$10.00Buy
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2/25/2026Boost Price Target$62.97$89.00Buy
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
2/18/2026Reiterated Rating$1.85$25.00Buy
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
2/17/2026Boost Price Target$17.00$28.00Buy
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
2/17/2026Reiterated Rating$77.90$147.00Buy
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
2/6/2026Reiterated Rating$20.02$32.00Buy
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1/28/2026Reiterated Rating$2.83$7.00Buy
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
1/27/2026Boost Price Target$2.08$7.00Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
1/21/2026Reiterated Rating$2.24Buy
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1/20/2026Initiated Coverage$2.10$7.00Buy
Trump's gold order: the announcement they won't put on the front page (Ad)

On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel

Request the free guide in 30 seconds and get positioned now
Novavax, Inc. stock logo
NVAX
Novavax
1/20/2026Reiterated Rating$8.61$19.00Buy
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1/20/2026Initiated Coverage$2.26$7.00Buy
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
1/15/2026Reiterated Rating$2.15$25.00Buy
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
1/6/2026Boost Price Target$98.64$147.00Buy
Alector, Inc. stock logo
ALEC
Alector
1/5/2026Upgrade$1.69Strong-Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
12/22/2025Initiated Coverage$2.30$10.00Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
12/22/2025Initiated Coverage$2.82$10.00Buy
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12/5/2025Reiterated Rating$20.11$32.00Buy
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
12/3/2025Reiterated Rating$2.27$25.00Buy
Biohaven Ltd. stock logo
BHVN
Biohaven
11/18/2025Reiterated Rating$8.27$16.00Buy
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
11/17/2025Initiated Coverage$12.01$27.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
11/13/2025Boost Price Target$5.94$16.00Buy
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
11/10/2025Reiterated Rating$41.65$85.00Buy
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
11/10/2025Reiterated Rating$4.69$9.00Buy
Biohaven Ltd. stock logo
BHVN
Biohaven
11/6/2025Lower Price Target$8.31$16.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
11/5/2025Reiterated Rating$25.34$39.00Buy
AC Immune stock logo
ACIU
AC Immune
11/4/2025Reiterated Rating$3.40$8.00Buy
Alector, Inc. stock logo
ALEC
Alector
10/22/2025Downgrade$3.21Neutral
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
10/22/2025Lower Price Target$11.02$23.00Buy
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
10/15/2025Reiterated Rating$2.04$9.00Buy
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
10/13/2025Boost Price Target$6.41$14.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
10/13/2025Boost Price Target$30.34$39.00Buy
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
9/30/2025Reiterated Rating$5.66$15.00Buy
Alector, Inc. stock logo
ALEC
Alector
9/25/2025Reiterated Rating$3.16$5.00Buy
Harrow, Inc. stock logo
HROW
Harrow
9/24/2025Reiterated Rating$48.85$63.00Buy
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
9/8/2025Initiated Coverage$42.24$72.00Buy
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
9/8/2025Reiterated Rating$1.76$9.00Buy
AC Immune stock logo
ACIU
AC Immune
9/8/2025Reiterated Rating$2.28$8.00Buy
Biohaven Ltd. stock logo
BHVN
Biohaven
8/19/2025Boost Price Target$15.71$60.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
8/18/2025Set Price Target$18.26$28.00Buy
Harrow, Inc. stock logo
HROW
Harrow
8/14/2025Boost Price Target$36.50$63.00Buy
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
7/10/2025Downgrade$104.77Hold
INmune Bio, Inc. stock logo
INMB
INmune Bio
7/1/2025Reiterated Rating$2.31Neutral
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
4/7/2025Lower Price Target$1.76$9.00Buy
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3/24/2025Lower Price Target$0.44$4.00Buy
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
1/28/2025Initiated Coverage$16.43$41.00Buy

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Top Stock Recommendations by Brokerage